Mediterr J Rheumatol 2021;32(1):74-80
Gout and AA-Amyloidosis: A Case-Based Review
Authors Information

1. Pirogov Russian National Research Medical University (RNRMU), Moscow, Russian Federation

2. I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

Margarita Gromova 

  1. Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 2018;25(4):215-9.
  2. Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin N Am 2018;44(4):585-03.
  3. Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid 2020;27(1):1-12.
  4. Dhillon V, Woo P, Isenberg D. Amyloidosis in the rheumatic diseases. Ann Rheum Dis 1989;48(8):696-01.
  5. Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61(10):1435-40.
  6. Horak P, Smrzova A, Krejci K, Tichy T, Zadrazil J, Skacelova M. Renal manifestations of rheumatic diseases. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013;157(2):98-104.
  7. Cytawa W, Teodorczyk J, Lass P. Nuclear imaging of amyloidosis. Pol J Radiol 2014;79:222-7.
  8. Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in Western countries. Kidney Dis (Basel, Switzerland) 2016;2(1):10-9.
  9. Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012;142:13580.
  10. Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 2014;6:369-77.
  11. Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore). 1960;39:405-67.
  12. Talbott JH. Gout. 3rd ed. New York: Grune and Stratton 1967:95-6.
  13. Levo Y, Shalev O, Rosenmann E, Eliakim M. Gout and amyloidosis. Ann Rheum Dis 1980;39:589-91.
  14. Rubinow A, Sonnemblick M. Amyloidosis secondary to polyarticular gout. Arthritis Rheum 1981;24:1425-27.
  15. Lens XM, Roselló R, Montoliu J, Solé M, Darnell A, Rotés J, et al. Amyloidosis secondary to gout. J Rheumatol 1985;12:1024-6.
  16. Jacobelli S, Vial S, Rosenberg H, Benson MD, Scheinberg MA. Amyloidosis secondary to gout. Identification with a monoclonal antibody to amyloid protein A. Clin Rheumatol 1988;7:534-37.
  17. Gumá M, Bayés B, Bonet J, Olivé A. Gout and secondary amyloid. Clin Rheumatol 1999;18:54-55.
  18. Vernerová Z, Rychlík I, Brunerová L, Dvořáková L, Pavelková A, Šebesta I. An unusual cause of renal amyloidosis secondary to gout: the first description of familial occurrence. Nucleosides Nucleotides Nucleic Acids 2006;25:1305-08.
  19. Ter Borg EJ, Wegewijs MA, de Bruin P. Gout and AA Amyloidosis A Case Report and Review of the Literature. JCR 2017;23(4):233-4.
  20. Brunger AF, Nienhuis HLA, van Rheenen RWJ, Korte MR, Bijzet J, Gans ROB, et al.  Obesity-induced AA amyloidosis: A diagnosis of exclusion Int J Clin Rheumatol 2020;15(2):26-2.
  21. Cantarini L, Rigante D, Brizi MG, Lucherini OM, Sebastiani GD, Vitale A, et al. Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 2012;44(7):664-73.
  22. Steiger S, Harper JL. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep 2014;16(1):392.
  23. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440(7081):237-41.
  24.  Amaral FA, Costa VV, Tavares LD, Sachs D, Coelho FM, Fagundes CT, et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout Arthritis Rheum 2012;64(2):474-84.
  25. Busso N, Ea HK. The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). Reumatismo 2012;63(4):230-7.
  26. Tavares LD, Galvão I, Costa VV, Batista NV, Rossi LCR, Brito CB, et al. Phosphoinositide-3 kinase gamma regulates caspase-1 activation and leukocyte recruitment in acute murine gout. J Leukoc Biol 2019;106(3):619-29.
  27. Bousoik E, Qadri M, Elsaid KA. CD44 Receptor Mediates Urate Crystal Phagocytosis by Macrophages and Regulates Inflammation in A Murine Peritoneal Model of Acute Gout. Sci Rep 2020;10(1):5748.
  28. Galvão I, de Carvalho RVH, Vago JP, Silva ALN, Carvalho TG, Antunes MM, et al. The role of annexin A1 in the modulation of the NLRP3 inflammasome. Immunology. 2020;160(1):78-89.
  29. Mitroulis I, Kambas K, Ritis K. Neutrophils, IL-1β, and gout: is there a link? Semin Immunopathol 2013;35(4):501-12.
  30. Blank N, Hegenbart U, Schönland S. Causes and treatment of systemic amyloidosis. Zeitschrift für Rheumatologie 2016;75(2):141-50.
  31.  Shtrasburg S, Pras M, Gal R, Salai M, Livneh A. Inhibition of the second phase of amyloidogenesis in a mouse model by a single-dose colchicine regimen. J Lab Clin Med 2001;138:107-11.
  32. Keizman IK, Greenwald M, Ravid M. Colchicine inhibition of the first phase of amyloid synthesis in experimental animals. Br J Exp Pathol 1976;57:686-8.
  33. Unverdi S, Inal S, Ceri M, Unverdi H, Batgi H, Tuna R, et al. Is colchicine therapy effective in all patients with secondary amyloidosis? Ren Fail 2013;35(8):1071-4.
  34. Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL. Colchicine: an ancient drug with novel applications. Br J Dermatol 2018;178(2):350-6.
  35. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006;20(5):879-96.
  36. Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol Mech Dis 2015;10(1):321-44.
  37. Lane T, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ. Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid 2017;24(3):189-93.
  38. Schlesinger N, MeulemeesterMD, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study Arthritis Res Ther 2011;13(2):R53.
  39. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. A. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study Ann Rheum Dis 2011;70(7):1264-71.
  40. Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 2019;29(2):363-6.
  41. Trabulus S, Korkmaz M, Kaya E, Seyahi N. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever. Clin Transplant 2018;32(8):e13345.
  42. Mariotte A, De Cauwer A, Po C, Abou-Faycal C, Pichot A, Paul N, et al. A mouse model of MSU-induced acute inflammation in vivo suggests imiquimod-dependent targeting of Il-1β as relevant therapy for gout patients. Theranostics 2020;10(5):2158-71.